Long-term outcomes in Waldenström macroglobulinemia (WM) patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy.

Authors: Karan Chohan, Lorenzo Gensini, Sherif Seif, Xiaowen Sun, Lei Feng, Janelle Sanchez, Melody R. Becnel, Mahmoud R. Gaballa, Hans C. Lee, Oren Pasvolsky, Krina K. Patel, Jing Christine Ye, Donna M. Weber, Robert Orlowski, Sheeba K. Thomas

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e19082

Source: Full article

---

Abstract

e19082